Predictive Oncology Files 8-K on Security Holder Matters

Ticker: AGPU · Form: 8-K · Filed: Sep 25, 2025 · CIK: 1446159

Sentiment: neutral

Topics: corporate-governance, security-holder-rights, amendment, voting

Related Tickers: PRED

TL;DR

PRED filed an 8-K detailing changes to security holder rights and corporate governance. Vote matters included.

AI Summary

Predictive Oncology Inc. filed an 8-K on September 25, 2025, reporting events that occurred on September 19, 2025. The filing indicates material modifications to security holder rights, amendments to its articles of incorporation or bylaws, and the submission of matters to a vote of security holders. It also includes Regulation FD disclosures and financial statements/exhibits.

Why It Matters

This 8-K filing signals significant corporate actions and potential changes affecting Predictive Oncology Inc.'s security holders, requiring their attention and potentially impacting their rights.

Risk Assessment

Risk Level: medium — The filing involves material modifications to security holder rights and amendments to corporate governance documents, which can introduce uncertainty and affect shareholder value.

Key Players & Entities

FAQ

What specific material modifications were made to the rights of Predictive Oncology Inc.'s security holders?

The filing indicates material modifications to the rights of security holders, but the specific details of these modifications are not elaborated upon in the provided text and would require reviewing the referenced exhibits or sections within the full filing.

What amendments were made to Predictive Oncology Inc.'s articles of incorporation or bylaws?

The filing states that amendments to the articles of incorporation or bylaws were made, but the exact nature of these amendments is not detailed in the provided summary text.

What matters were submitted to a vote of Predictive Oncology Inc.'s security holders?

The filing confirms that matters were submitted to a vote of security holders, but the specific proposals or resolutions are not listed in the provided text.

When was the earliest event reported in this 8-K filing?

The earliest event reported in this 8-K filing occurred on September 19, 2025.

What is the SIC code for Predictive Oncology Inc. and what industry does it represent?

The SIC code for Predictive Oncology Inc. is 3842, which represents 'ORTHOPEDIC, PROSTHETIC & SURGICAL APPLIANCES & SUPPLIES'.

Filing Stats: 1,111 words · 4 min read · ~4 pages · Grade level 11.3 · Accepted 2025-09-25 08:05:53

Key Financial Figures

Filing Documents

03. Material Modification to Rights of Security Holders

Item 3.03. Material Modification to Rights of Security Holders The information set forth under Item 5.03 is incorporated into this Item 3.03 by reference.

03. Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year

Item 5.03. Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year On September 19, 2025, as described below, the stockholders of Predictive Oncology Inc. (the "Company") approved an amendment to the Company's certificate of incorporation, as amended (the "Charter"), to effect a one-for-fifteen reverse stock split of the outstanding shares of the Company's common stock, par value $0.01 per share (the "Common Stock"). Following such approval, the Company filed a Certificate of Amendment to the Charter with the Secretary of State of the State of Delaware on September 22, 2025, to effect the reverse stock split, effective as of 5:00 PM ET on September 29, 2025 (the "Effective Time"). The Common Stock is expected to begin trading on a reverse-split-adjusted basis on the Nasdaq Capital Market as of the open of trading on September 30, 2025, under the existing ticker symbol "POAI." The new CUSIP number for the Common Stock is 74039M408. As a result of the reverse stock split, at the Effective Time, every 15 shares of issued and outstanding Common Stock will be automatically combined into one issued and outstanding share of Common Stock, without any change in the par value per share. No fractional shares will be issued as a result of the reverse stock split and any fractional shares that would otherwise have resulted from the reverse stock split will be rounded up to the next whole number. The reverse stock split does not change the total number of authorized shares of Common Stock or preferred stock. The information set forth herein does not purport to be complete and is qualified in its entirety by reference to the full text of the Certificate of Amendment, which is filed as Exhibit 3.1 to this Current Report on Form 8-K and is incorporated into this Item 5.03 by reference.

07. Submission of Matters to a Vote of Security Holders

Item 5.07. Submission of Matters to a Vote of Security Holders On September 19, 2025, the Company held a Special Meeting of Stockholders (the "Special Meeting"). As of August 18, 2025, the record date for the Special Meeting, there were 10,892,657 shares of common stock outstanding and entitled to vote. The results of the matters submitted to a vote of the stockholders at the Special Meeting are set forth below: 1. To approve an amendment of the Company's certificate of incorporation, as amended (the "Charter") to effect a reverse stock split of the outstanding shares of its common stock at a ratio of one-for-fifteen (1:15) (the "Reverse Split Proposal") Stockholders approved the Reverse Split Proposal by the following votes: Voted For Voted Against Abstentions Broker Non-Votes 3,739,479 1,317,568 54,693 1 2. To approve the issuance of up to $10,000,000 of the Company's common stock pursuant to a Standby Equity Purchase Agreement dated July 1, 2025, for purposes of complying with Nasdaq listing rule 5635 (the "Nasdaq Proposal") Stockholders approved the Nasdaq Proposal by the following votes: Voted For Voted Against Abstentions Broker Non-Votes 1,301,709 355,445 88,591 3,365,996 3. To approve the adjournment of the Special Meeting in the event that the number of shares of common stock present or represented by proxy at the meeting and voting "FOR" the adoption of the foregoing proposals are insufficient to approve such proposals (the "Adjournment Proposal") Stockholders approved the Adjournment Proposal by the following votes: Voted For Voted Against Abstentions Broker Non-Votes 3,850,719 1,146,863 114,155 4 Although stockholders approved the Adjournment Proposal, because a quorum was present and stockholders approved the Reverse Split Proposal and the Nasdaq Proposal, no adjournment of the Special Meeting was necessary.

01. Regulation FD Disclosure

Item 7.01. Regulation FD Disclosure On September 25, 2025, the Company issued a press release regarding the reverse stock split. The press release is attached hereto as Exhibit 99.1 to this Current Report on Form 8-K and is incorporated into this Item 7.01 by reference. The information set forth in this Item 7.01 and the attached Exhibit 99.1 shall not be deemed "filed" for purposes of the Securities Exchange Act of 1934 (the "Exchange Act") or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference in any filing under the Securities Act of 1933 or the Exchange Act, regardless of any general incorporation language in such filing.

01. Financial Statements and Exhibits

Item 9.01. Financial Statements and Exhibits (d) Exhibits 3.1 Certificate of Amendment of Certificate of Incorporation 99.1 Press Release dated September 25, 2025 104 Cover Page Interactive Data File (embedded within the Inline XBRL document) SIGNATURE Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the Registrant has duly caused this Current Report on Form 8-K to be signed on its behalf by the undersigned hereunto duly authorized. PREDICTIVE ONCOLOGY INC. Date: September 25, 2025 By: /s/ Josh Blacher Name: Josh Blacher Title: Interim Chief Financial Officer

View Full Filing

View this 8-K filing on SEC EDGAR

View on Read The Filing